Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Drugs for Terminally Ill Clear New Hurdle

By R&D Editors | March 26, 2014

A proposal to allow terminally ill people access to drugs that are still completing clinical trials cleared its first test in the Colorado Legislature on Tuesday.
 
The House Health, Insurance & Environment Committee voted 10-1 for the measure after it was amended to make clear that the experimenting patients, not their insurers, are responsible for health costs after taking experimental drugs.
 
“This is a bill about personal choice,” said one of the bill’s sponsors, Rep. Joann Ginal, D-Fort Collins.
 
The bill now awaits a vote by the full House.
 
So-called “Right To Try” proposals are pending in several states. The Goldwater Institute, a Phoenix-based libertarian think tank, has promoted the measure as a way to help terminally ill people who don’t have time to wait for years of clinical trials for new medications.
 
The legislation still requires doctors to sign off on the use of an investigational product.
 
The only vote against the measure came from Rep. Rhonda Fields, D-Aurora, who worried the insurance exemption could leave terminally ill without coverage even for health problems unrelated to the unapproved drugs.
 
“I’m concerned about the lack of insurance when someone is dying,” Fields said.
 
Another sponsor of the bill, Republican Rep. Janak Joshi, of Colorado Springs, insisted there need to be liability protections for hospitals and insurers.
 
“Patients will have to recognize that they’re responsible,” Joshi said.
 
Pharmaceutical companies are neutral on the measure, and experimental drugs used outside clinical trials won’t affect the drugs’ path to wider use, sponsors said Tuesday.
 
Similar “Right To Try” proposals are pending in legislatures in Arizona, Louisiana and Missouri.
 
Date: March 26, 2014
Source: Associated Press
Author: Kristen Wyatt

Related Articles Read More >

Certara’s COVID vaccine model is focus of Episode 8 of R&D 100 – The Podcast
New dangers in the woods — and the hope that research offers us
PerkinElmer participating at Bio-IT World Conference & Expo
Nalu Medical’s mIPG is focus of Episode 7 of R&D 100 – The Podcast
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2022 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars